Shared pathophysiology and therapeutic repurposing in Alzheimer's disease and type 2 diabetes: a critical review of convergent mechanisms and clinical challenges.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing shared mechanisms and repurposing strategies without systematic meta-analysis
PubMed 42247872 · doi:10.1016/j.bioorg.2026.110044
What was done
This narrative review synthesized literature on shared molecular pathways between Alzheimer's disease (AD) and type 2 diabetes mellitus (T2DM)—including insulin resistance, oxidative stress, the AGE-RAGE axis, amyloidogenic misfolding (Aβ and IAPP), endoplasmic reticulum stress, and vasculopathy. It evaluated clinical and preclinical evidence for repurposing major antidiabetic drug classes (insulin analogues, metformin, sulfonylureas, thiazolidinediones, GLP-1 receptor agonists, DPP-4 inhibitors, and amylin modulators) for AD treatment.
What was found
The abstract reports no quantitative data or statistical effect sizes. It qualitatively describes the shared pathophysiology between AD and T2DM and identifies critical sources of clinical inconsistency in drug repurposing trials, including APOE ε4 genotype heterogeneity, disease stage dependency, blood-brain barrier permeability limitations, and off-target safety risks.
Why it matters
Synthesizes the metabolic framework of Alzheimer's disease to explain inconsistent clinical trial results with antidiabetic agents and highlights the need for biomarker-stratified, early-stage intervention.
Limits
As a narrative review, it presents no original empirical human data or quantitative meta-analysis. Search strategy, study inclusion criteria, sample sizes, and detailed outcome metrics are not provided in the abstract.
Cited by
- supports Alzheimer's disease is biologically characterized in many ways as type 3 diabetes.